Purdue Pharma has appointed Marcelo Bigal to serve as the Stamford, CT-based company’s chief medical officer. Bigal comes to Purdue from Teva Pharmaceutical (NYSE: [[ticker:TEVA]]), where he was chief scientific officer. Before joining Teva, Bigal was chief medical officer of Labrys Biologics, which Teva acquired in 2014 in order to add the company’s migraine drug candidate to its pipeline.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
